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ORIGINAL INVESTIGATION
Palaeolithic diet decreases fasting 
plasma leptin concentrations more  
than a diabetes diet in patients with type 2 
diabetes: a randomised cross‑over trial
Maelán Fontes‑Villalba1,6*, Staffan Lindeberg1, Yvonne Granfeldt2, Filip K. Knop3, Ashfaque A. Memon1, 
Pedro Carrera‑Bastos1, Óscar Picazo4, Madhvi Chanrai5, Jan Sunquist1, Kristina Sundquist1 and Tommy Jönsson1
Abstract 
Background: We have previously shown that a Palaeolithic diet consisting of the typical food groups that our ancestors ate 
during the Palaeolithic era, improves cardiovascular disease risk factors and glucose control compared to the currently rec‑
ommended diabetes diet in patients with type 2 diabetes. To elucidate the mechanisms behind these effects, we evaluated 
fasting plasma concentrations of glucagon, insulin, incretins, ghrelin, C‑peptide and adipokines from the same study.
Methods: In a randomised, open‑label, cross‑over study, 13 patients with type 2 diabetes were randomly assigned 
to eat a Palaeolithic diet based on lean meat, fish, fruits, vegetables, root vegetables, eggs and nuts, or a diabetes 
diet designed in accordance with current diabetes dietary guidelines during two consecutive 3‑month periods. The 
patients were recruited from primary health‑care units and included three women and 10 men [age (mean ± SD) 
64 ± 6 years; BMI 30 ± 7 kg/m2; diabetes duration 8 ± 5 years; glycated haemoglobin 6.6 ± 0.6 % (57.3 ± 6 mmol/
mol)] with unaltered diabetes treatment and stable body weight for 3 months prior to the start of the study. Outcome 
variables included fasting plasma concentrations of leptin, adiponectin, adipsin, visfatin, resistin, glucagon, insulin, 
C‑peptide, glucose‑dependent insulinotropic polypeptide, glucagon‑like peptide‑1 and ghrelin. Dietary intake was 
evaluated by use of 4‑day weighed food records.
Results: Seven participants started with the Palaeolithic diet and six with the diabetes diet. The Palaeolithic diet 
resulted in a large effect size (Cohen’s d = −1.26) at lowering fasting plasma leptin levels compared to the diabetes 
diet [mean difference (95 % CI), −2.3 (−5.1 to 0.4) ng/ml, p = 0.023]. No statistically significant differences between 
the diets for the other variables, analysed in this study, were observed.
Conclusions: Over a 3‑month study period, a Palaeolithic diet resulted in reduced fasting plasma leptin levels, but 
did not change fasting levels of insulin, C‑peptide, glucagon, incretins, ghrelin and adipokines compared to the cur‑
rently recommended diabetes diet.
Trial registration: ClinicalTrials.gov NCT00435240
Keywords: Palaeolithic diet, Type 2 diabetes, Glucagon, Leptin, Lipotoxicity, Adiposopathy, Evolution
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The metabolic syndrome represents a cluster of symp-
toms including abdominal obesity, insulin resistance, 
dyslipidemia, and high fasting glucose and blood pres-
sure [1]. The condition is associated with a fivefold 
increased risk of type 2 diabetes, which is characterized 
by insulin resistance [2] and β-cell failure [3]. Lifestyle 
plays a prominent role in the pathophysiology of the met-
abolic syndrome and type 2 diabetes [4, 5]. Specifically, 
an unhealthy diet with chronic caloric surplus induces 
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hyperinsulinemia leading to ectopic lipid deposition 
(lipotoxicity) in the heart, liver, pancreas and muscle [6–
8], increasing the risk of the metabolic syndrome, fatty 
liver, fatty heart and type 2 diabetes [7].
Interestingly, insulin resistance has been suggested to 
be a consequence and a protective mechanism against 
lipotoxicity [6–10]. Leptin resistance is a possible player 
in the roadmap to the metabolic syndrome and type 2 
diabetes [7], and it has been suggested that leptin can 
protect against lipotoxicity [7]. Lipotoxicity can generate 
α-cell insulin resistance resulting in hyperglucagonae-
mia and increased hepatic glucose production [10]. It is 
increasingly recognized that the recent (in an evolution-
ary perspective) introduction of staple food groups such 
as cereal grains, dairy products and refined sugars in 
the human diet has occurred too recently for the human 
genome to have completely adapted [11].
In a previous publication from this trial, we reported 
significant improvements in glycated haemoglobin 
(HbA1c), blood lipids, blood pressure, weight and waist 
circumference [12] along with increased satiety [13] in 
patients with type 2 diabetes consuming a Palaeolithic 
diet, as compared to the officially recommended diet for 
patients with type 2 diabetes (diabetes diet) [14].
The abovementioned pathophysiological changes pro-
duce adaptations in other hormones and endocrine 
axes. Therefore, our aim was to investigate if the ben-
eficial effects from a Palaeolithic diet could be tentatively 
explained by associated changes in adipokines, glucagon, 
incretins and ghrelin, and here we present new data on 
the fasting levels of these hormones from our previous 
study [12] (Additional file 1).
Methods
Approval of the study was obtained from the regional 
Medical Ethics Committee and the trial was registered at 
ClinicalTrials.gov (Identifier: NCT00435240).
Participants
Patients with type 2 diabetes without insulin treatment 
were recruited from primary health-care units in the 
Lund area of Sweden. Details about inclusion and exclu-
sion criteria and patient characteristics (Table  1) have 
previously been published [12]. All recruited subjects 
were given oral and written study information prior to 
signing a consent form to participate in the study and 
were then further assessed for eligibility.
Design
The study design and generation of random allocation 
sequence have been reported in detail previously [12]. 
In short, the study was a randomised, cross-over, dietary 
intervention study in which all eligible subjects were 
informed of the intention to compare two healthy diets 
and that it was not known whether one diet might be 
superior to the other. After randomisation, there was no 
blinding of dietary assignment to study participants, nor 
to those administering the interventions or assessing the 
outcomes. At study start, all subjects were randomised, 
by use of opaque envelopes, to start with either a dia-
betes diet designed in accordance with official recom-
mendations [14] or a Palaeolithic diet [12]. Immediately 
after randomisation, all subjects received oral and written 
information about their respective initial diet individu-
ally from diabetes nurses. After 3  months, all subjects 
switched diets and received new oral and written infor-
mation about the new diet. Advice about regular physical 
activity was given to all subjects.
Diets
The information on the diabetes diet stated that it aimed 
to provide evenly distributed meals with an increased 
intake of vegetables, root vegetables, dietary fibre, whole-
grain bread and other whole-grain cereal products, fruits 
and berries, and a decreased intake of total fat with more 
unsaturated fat. It was recommended that salt intake 
should be kept below 6  g per day. The information on 
the Palaeolithic diet stated that it should be based on 
lean meat, fish, fruit, leafy and cruciferous vegetables, 
root vegetables, eggs and nuts, while avoiding—as far as 
possible—dairy products, cereal grains, beans, refined 
fats, sugar, candy, soft drinks, beer and added salt. The 
following items were recommended in limited amounts 
for the Palaeolithic diet: eggs (≤2 per day), nuts (prefer-
entially walnuts), dried fruit, potatoes (≤1 medium-sized 
per day), rapeseed or olive oil (≤1 tablespoon per day) 
and wine (≤1 glass per day). The recommended intake 
of the other foods was not restricted and no advice was 
given with regard to the proportions of food categories 
(e.g. animal vs. plant foods). The evolutionary rationale 
for a Palaeolithic diet and its potential benefits have been 
outlined previously [15] and detailed nutritional compo-
sitions of the diets can be found in our previous report 
[12].
Procedures
An oral glucose tolerance test (OGTT) was performed in 
the morning after obtaining venous blood samples and 
measurements of blood pressure, weight and waist cir-
cumference using standard methods [12] at the start of 
the study, after 3 months (when switching to a new diet) 
and at the end of the study (after 6  months). Samples 
were collected in EDTA-containing tubes and centri-
fuged for 10 min at 4 °C. Plasma was then aliquoted and 
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stored at −80 °C until analysis. Outcome variables in the 
present study included fasting plasma concentrations of 
leptin, adiponectin, adipsin, visfatin, resistin, glucagon, 
insulin, C-peptide, GIP, GLP-1 and ghrelin.
Assessment of conditions of frozen blood samples
To assess the condition of the frozen blood samples we 
compared new analyses of insulin to older ones. The 
newly analyzed insulin values were on average 27  % 
lower than older analyses and the standard deviation had 
increased by 66  %. However, the Pearson correlation of 
0.72 (adjusted R2  =  0.51) between new and old insulin 
values for the same individual and time were highly cor-
related (p < 0.0001).
Analyses
The Bio-Plex pro™ human diabetes panel (Bio-Rad Inc., 
Hercules, CA, USA) a Luminex-based magnetic bead assay, 
was used to quantify insulin, C-peptide, ghrelin, GIP, GLP-
1, glucagon, leptin, resistin and visfatin and a separate Bio-
Plex assay was used to quantify adiponectin and adipsin 
(due to different dilution factor) in plasma according to the 
manufacturer’s instructions. Each run included controls of 
known concentration for each cytokine and a blank.
Table 1 Baseline characteristics
Data is presented as mean values with SD in brackets, unless stated
ACE angiotensin converting enzyme, GIP glucose‑dependent insulinotropic polypeptide, GLP-1 glucagon‑like peptide‑1
All Diabetes first (6/13) Palaeolithic first (7/13)
Sex male/female (n) 10/3 4/2 6/1
Age (years) 64 (6) 63 (6) 66 (6)
Height (cm) 171 (5) 170 (6) 172 (4)
Weight (kg) 87 (17) 92 (20) 82 (13)
BMI (kg/m2) 30 (7) 32 (8) 28 (4)
Waist circumference (cm) 103 (14) 109 (17) 97 (9)
Diabetes duration (years) 8 (5) 11 (6) 6 (4)
Diabetic values at OGTT yes/no (n) 12/1 6/0 6/1
Lipid lowering drug (=statin) yes/no (n) 8/5 4/2 4/3
Drugs per day 4.3 (2.3) 3.7 (1.8) 4.9 (2.7)
Antihypertensive drugs per day 1.5 (1.5) 1.2 (1.2) 1.9 (1.7)
 Beta‑blocker yes/no (n) 4/9 1/5 3/4
 Thiazide yes/no (n) 4/9 1/5 3/4
 ACE inhibitor yes/no (n) 5/8 2/4 3/4
 Angiotensin‑II receptor blocker yes/no (n) 4/9 2/4 2/5
 Calcium channel blocker yes/no (n) 3/10 1/5 2/5
Anti‑diabetic drugs per day 1.2 (0.9) 1.5 (0.8) 0.9 (0.9)
 Metformin yes/no (n) 9/4 5/1 4/3
 Dosage, mg/day 1031 (864) 1283 (950) 814 (790)
 Sulphonylurea yes/no (n) 3/10 2/4 1/6
 Thiazolidinedione yes/no (n) 3/10 2/4 1/6
Plasma adiponectin (µg/ml) 4.8 (4.16) 4.8 (2.5) 4.9 (5.4)
Plasma adipsin (ng/ml) 797 (157) 804 (218) 792 (178)
Plasma C‑peptide (pg/ml) 487 (275) 437 (276) 531 (289)
Plasma ghrelin (pg/ml) 568 (129) 613 (165) 530 (82)
Plasma GIP (pg/ml) 232 (91.6) 226 (83) 237 (105)
Plasma GLP‑1 (pg/ml) 26.8 (3.39) 26.4 (4.5) 27.1 (2.4)
Plasma glucagon (pg/ml) 425 (44.34) 435 (52.4) 417 (38.4)
Plasma leptin (ng/ml) 9.84 (12.18) 12.1 (17) 7.9 (6.8)
Plasma resistin (ng/ml) 2.21 (0.39) 2.3 (0.4) 2.1 (0.4)
Plasma visfatin (ng/ml) 2.52 (0.75) 2.7 (0.5) 2.4 (0.7)
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Statistics
The statistical power calculations were based on initial pri-
mary outcomes of this intervention and previously pub-
lished [12]. Data were analysed for normality (determined 
by Q–Q plots and the Shapiro–Wilk test in SPSS) and 
logarithmically transformed when necessary. If data did 
not show reasonable normal distribution after logarithmic 
transformation, the Wilcoxon matched pairs signed rank 
sum test was used, otherwise a paired t test was used. To 
analyse the difference between diets in their effects on out-
comes we compared the absolute values at the end of each 
diet. In order to check for carry-over effects, t tests were 
used to compare mean values of outcome variables for the 
group starting with the Palaeolithic diet with those for the 
group starting with the diabetes diet. In order to check for 
period effects, t tests were used to compare the effects of 
the first and second diets. We performed post hoc analy-
sis using bivariate correlations between the outcome vari-
ables presented in Table 2 and outcome variables related to 
glucose homeostasis and satiation. Bivariate correlations 
were also performed between the outcome variables pre-
sented in Table 2 and dietary variables. Outcome variables 
with significant correlations were entered in Simple Lin-
ear Regression. Significance was set at p < 0.05. All t tests 
were two-sided. Due to multiple outcome measures prob-
lem in this post hoc analysis a multiple outcome measures 
correction was made using QuickCalcs online pro-
vided by GraphPad Software (http://www.graphpad.com/
quickcalcs/interpretPValue1/). Statistical analysis was per-
formed with SPSS for Mac Version 20 (IBM SPSS Statistics 
for Mac, Version 20.0, IBM Corp., Armonk, NY, USA).
Results
Participant flow
All reported analyses are per protocol analyses on the 13 
participants (3 women, 10 men) who completed the trial 
(Fig.  1). Four subjects were excluded for the following 
reasons: one starting with Paleolithic diet was wrongly 
included with ongoing warfarin treatment, one starting 
with Paleolithic diet was unwilling to continue due to 
abdominal pains and bloating, one starting with diabe-
tes diet was excluded after developing leukemia, and one 
starting with diabetes diet was excluded after developing 
heart failure. Dates defining the periods of recruitment 
and follow-up, and side effects have been previously pub-
lished [12].
Baseline data
Individual characteristics regarding anthropometric 
measurements, medication and outcome variables have 
been reported in detail previously [12] and are sum-
marised in Table  1. The participants starting with the 
Palaeolithic diet compared to those starting with the dia-
betes diet did not differ at baseline for any of the outcome 
variables (Table  1). No carry-over or period effect was 
observed.
Table 2 Hormone levels, and weight, after the Palaeolithic diet and diabetes diet
Data are mean ± standard deviation (95 % CI)
Significance tests are paired t test for normally distributed data and Wilcoxon matched pairs signed rank sum test for non‑normally distributed data
Significant p values are indicated by italics font
GIP glucose‑dependent insulinotropic polypeptide, GLP-1 glucagon‑like peptide‑1
a p for difference between diets
b Data non‑normally distributed (Wilcoxon matched pairs signed rank sum test)
c Old insulin values previously published
Outcome Palaeolithic diet Diabetes diet Delta diets pa
Adiponectin (µg/ml) 5.2 ± 4.4 (2.5 to 7.9) 5.7 ± 5.4 (2.5 to 9.1) −0.5 ± 1.2 (−1.3 to 0.2) 0.153
Adipsin (ng/ml) 787 ± 182 (677 to 896) 776 ± 153 (684 to 869) 10 ± 79 (−37 to 58) 0.650
C‑peptide (pg/ml) 455 ± 224 (319 to 590) 412 ± 204 (289 to 535) 43 ± 262 (−116 to 201) 0.644
Ghrelin (pg/ml) 540 ± 97 (481 to 598) 566 ± 145 (478 to 654) −26 ± 74 (−70 to 18) 0.226
GIP (pg/ml) 254 ± 266 (93 to 415) 186 ± 75 (141 to 232) 68 ± 264 (−92 to 227) 0.600b
GLP‑1 (pg/ml) 27 ± 9.3 (22 to 33) 27 ± 3.7 (25 to 29) 0.4 ± 7.7 (−4.3 to 5.12) 0.235b
Glucagon (pg/ml) 409 ± 40 (385 to 433) 431 ± 51 (400 to 463) −22 ± 43 (−48 to 3.9) 0.089
Insulin (pg/ml) 248 ± 138 (165 to 332) 336 ± 327 (138 to 533) −87 ± 240 (−232 to 58) 0.266
Insulinc (pg/ml) 401 ± 174 (296 to 506) 391 ± 115 (322 to 461) 9.8 ± 172 (−94 to 114) 0.840
Leptin (ng/ml) 5.1 ± 4.9 (2.1 to 8.0) 7.4 ± 8.3 (2.4 to 12) −2.3 ± 4.6 (−5.1 to 0.4) 0.023b
Resistin (ng/ml) 2.5 ± 0.9 (1.9 to 3.0) 2.3 ± 0.6 (2.0 to 2.7) 0.2 ± 0.6 (−0.2 to 0.5) 0.356
Visfatin (ng/ml) 2.4 ± 0.7 (2.0 to 2.9) 2.5 ± 0.6 (2.1 to 2.8) −0.1 ± 0.5 (−0.3 to 0.3) 0.906
Weight (kg) 81 ± 13 (74 to 88) 84 ± 15 (76 to 92) −3.3 ± 3.8 (−5.7 to −1.0) 0.008
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Outcomes
The absolute level of plasma leptin after the Palaeo-
lithic diet was lower than after the diabetes diet (large 
effect size, Cohen’s d  =  −1.26; p  =  0.023) (Table  2; 
Fig.  2) [16, 17]. When one outlier (more than 3 SDs) 
was excluded, the mean difference of leptin after the 
diets was normally distributed and the difference 
remained significant (p  =  0.031). However, due to 
multiple outcome measures problem the probabilities 
of having a p value less than 0.023 just by chance in 
our dataset is 20.8 %.
The absolute level of glucagon at the end of the Palaeo-
lithic diet was lower than at the end of the diabetes diet 
(moderate effect size, Cohen’s d = −0.51), but this dif-
ference did not reach statistical significance (p = 0.089) 
(Table 2; Fig. 2).
As previously reported, weight loss was significantly 
greater (−3.3 kg) after the Palaeolithic diet than the dia-
betes diet (p = 0.008).
No statistically significant differences between the diets 
for the other variables were observed (Table 2).
Correlations and linear regression
In post hoc analysis of within-subject differences (value 
after the Palaeolithic diet minus value after the diabetes 
diet) we found that leptin correlated with fasting plasma 
insulin (Spearman’s correlation 0.55, p  =  0.049), grams 
of dietary fat (Spearman’s correlation −0.66, p = 0.013), 
percentage of dietary fat (Spearman’s correlation −0.55, 
p  =  0.049), grams of dietary saturated fat (Spearman’s 
correlation −0.59, p = 0.033), grams of dietary fatty acid 
C16:0 (Spearman’s correlation −0.57, p  =  0.041), and 
grams of dietary fatty acid C18:0 (Spearman’s correlation 
−0.55, p =  0.049); glucagon correlated with area under 
the curve (AUC) for insulin0–120  min (Pearson’s correla-
tion 0.94, p  =  0.015), stimulated AUC insulin0–120  min 
(Pearson’s correlation 0.55, p  =  0.047), fasting plasma 
insulin (Pearson’s correlation 0.63, p  =  0.019), satiety 
quotient for dietary glycaemic index per meal (Pearson’s 
correlation −0.56, p  =  0.045), dietary glycaemic load 
(Pearson’s correlation 0.63, p = 0.021), dietary glycaemic 
index (Pearson’s correlation 0.73, p = 0.005), dietary fatty 
acid C20:5 (EPA) (Pearson’s correlation 0.58, p = 0.037), 
Fig. 1 Flow diagram of participant recruitment
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dietary fatty acid C22:6 (DHA) (Pearson’s correlation 
0.57, p =  0.04) and dietary vitamin B12 (Pearson’s cor-
relation 0.57, p = 0.041) (Table 3).
Discussion
This small trial showed that a Palaeolithic diet decreased 
fasting plasma leptin, but did not affect fasting levels of 
insulin, C-peptide, glucagon, incretins, ghrelin and adi-
pokines significantly compared to the currently recom-
mended diabetes diet.
Weight loss interventions have been shown to decrease 
leptin concentrations [18], and in our trial leptin 
decreased only with the intervention that induced weight 
loss, i.e. the Palaeolithic diet. However, post hoc analysis 
revealed no correlation between difference in weight loss 
and leptin after the diets (Spearman’s correlation 0.11, 
p = 0.721).
Interestingly, genetic and in vitro studies indicate insuf-
ficient adaptation of the human leptin system to a diet 
based on cereal grains [19, 20]. Therefore cereal grains 
could hypothetically lead to leptin resistance and higher 
leptin values. Our finding of lower leptin following a Pal-
aeolithic diet virtually devoid of cereal grains compared 
to a diabetes diet with cereal grains supports this notion, 
and could represent the mechanism behind our previous 
findings of improved glucose control and blood lipids 
[12] and greater satiety per calorie from the Palaeolithic 
diet [13].
In our study there was a non-significant lower fasting 
glucagon levels after the Palaeolithic diet compared to 
the diabetes diet, which could be a result of the ameliora-
tion of leptin sensitivity in the pancreatic islets. However, 
this hypothesis should be tested in trials with adequate 
statistical power.
Due to the small sample size, we were not able to con-
duct a multivariate analysis adjusting for weight loss to 
explore the independent effect of the Palaeolithic diet 
on leptin and glucagon. Therefore, our results might be 
explained by the weight loss produced only during the 
Palaeolithic diet, as already mentioned.
Insulin plays a central role in type 2 diabetes, but 
despite this we found no difference in fasting insulin 
between the diets. Compared to baseline, there was a sig-
nificant decrease in insulin (p = 0.004 and 0.023, for old 
and new insulin analysis, respectively) after the Palaeo-
lithic diet, which may be explained by weight loss.
Adiponectin appears to play an important role in type 
2 diabetes due to its anti-inflammation, antiatherogenic, 
and insulin-sensitizing properties [21], yet we found no 
difference between the diets. However, there is some con-
troversy regarding the beneficial effects of adiponectin in 
type 2 diabetes [22–25].
In the exploratory analysis there was a positive correla-
tion between change in fasting leptin and insulin, which 
could be explained by the mechanisms discussed above 
and recently reviewed by Nolan et al. [8]. This finding is 
consistent with other studies where a positive correlation 
between fasting leptin and insulin has also been shown 
[26, 27]. It has been shown that treatment with recom-
binant human leptin does not improve insulin sensitiv-
ity in obese patients with type 2 diabetes [28], contrary 
to what happens in patients with severe leptin deficiency 
[29]. This might support the notion that patients with 
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type 2 diabetes suffer from leptin resistance. Interest-
ingly, within-subject differences in fasting leptin corre-
lated negatively with the intake of total fat (in grams and 
percent) and C16:0 and C18:0 fatty acids. These results 
are consistent with a randomised controlled trial where 
a low-fat diet lowered leptin levels more than a high-fat 
diet [30]. On the other hand, in a well controlled study 
leptin levels were higher with a low-fat diet than a low-
glycaemic index or very low–carbohydrate diet [31]. 
Other trials found no effect of fat restriction on leptin 
levels [32, 33]. This inconsistency in results may be due to 
differences between individuals in gene variants related 
to leptin physiology [34].
Comparison with findings from other studies
In a previous trial from our group, leptin decreased sig-
nificantly during Palaeolithic and Mediterranean diets, 
respectively, with no differences between diets, but after 
exclusion of one outlier with a high grain intake in the 
Palaeolithic diet group there was a significantly greater 
decrease in leptin in this group [35]. Interestingly, in the 
same study there was a strong correlation (Pearson’s cor-
relation 0.50, p  =  0.008) between change in leptin and 
intake of cereals [35]. Nevertheless, contrary to our pre-
vious finding there was no correlation in the data (Spear-
man’s correlation 0.22, p = 0471). Additionally, data from 
the present trial indicated that the Palaeolithic diet is 
Table 3 Exploratory analysis
Exploratory analysis was conducted to check for significant correlations between the outcome variables presented in Table 2 and outcome variables related to 
glucose homeostasis and satiation. Bivariate correlations were also performed between the outcome variables presented in Table 2 and dietary variables. This analysis 
consisted in bivariate Pearson or Spearman’s (for non normally distributed variables) correlation between within‑subject differences in outcome and dietary variables. 
Normally distributed outcomes that were significant in Pearson’s correlation were entered into simple linear regression
a Pearson’s correlation for normally distributed variables
b Spearman’s correlation for non normally distributed variables
c p value for bivariate correlation and simple linear regression
Pearson’s correlation ra Spearman’s correlation rb Adjusted R2 pc
Leptin (ng/ml) versus
 Fasting insulin (ng/ml) 0.555 0.049
 Fat (g) −0.665 0.013
 Fat (%) −0.555 0.049
 SAF (g) −0.593 0.033
 Fatty acid C16:0 (g) −0.571 0.041
 Fatty acid C18:0 (g) −0.555 0.049
Glucagon (pg/ml) versus
 AUC insulin0‑120 (nmol/l min) 0.946 0.383 0.015
 Stimulated AUC insulin0‑120 (nmol/l min) 0.558 0.249 0.047
 Fasting plasma insulin (pmol/l) 0.637 0.352 0.019
 Satiety quotient for glycaemic index per meal (RS) −0.562 0.254 0.045
 Glycaemic load (g) 0.63 0.342 0.021
 Glycaemic index 0.731 0.491 0.005
 Fatty acid C20:5, n‑3, EPA (g) 0.581 0.277 0.037
 Fatty acid C22:6, n‑3, DHA (g) 0.575 0.27 0.04
 Vitamin B‑12 (µg) 0.571 0.265 0.041
Adipsin (ng/ml) versus
 Satiety quotient for GL per meal (RS/kg) 0.581 0.277 0.037
GIP (pg/ml) versus
 Fasting plasma insulin (pmol/l) 0.555 0.049
GLP‑1 (pg/ml) versus
 Stimulated AUC insulin (nmol/l min) 0.654 0.015
 AUC insulin (nmol/l min) 0.67 0.012
Resistin (ng/ml) versus
 Fasting plasma insulin (pmol/l) −0.728 0.451 0.041
 Satiety quotient for GL per meal (RS/kg) 0.810 0.598 0.015
Visfatin (ng/ml) versus
 Fasting plasma glucose (mmol/l) −0.557 0.248 0.048
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more satiating than the diabetes diet [13], consistent with 
another trial from our group [35]. Other randomised 
clinical trials have shown beneficial effects of a Palaeo-
lithic diet compared with other healthy diets on car-
diovascular risk factors [36] and body fat [37]. A recent 
systematic review and meta-analysis, where these studies 
were included [12, 36–38], showed that a Palaeolithic diet 
improves some components of the metabolic syndrome 
more than the healthy control diets [39].
The Mediterranean diet has been the focus of several 
publications regarding its role in the metabolic syndrome 
and type 2 diabetes [40–43]. A systematic review and meta-
analysis showed that the Mediterranean diet was superior 
to control diets for all components of the metabolic syn-
drome [44]. Another systematic review and meta-analysis 
concluded that the Mediterranean diet decreased HbA1c, 
but not fasting glucose, more than control diets but not 
more than the Palaeolithic diet [42]. An important con-
sideration with respect to the characteristics of Mediter-
ranean and Palaeolithic diets concerns their resemblance. 
Both emphasize a high intake of whole unprocessed foods, 
specifically: fruits, vegetables, fish, nuts, and olive oil, while 
the limitation in the intake of wholegrain cereals and leg-
umes in the Paleolithic diet is the main difference. In light 
of the role that inflammation and oxidative stress might 
play in glycaemic control in type 2 diabetes [45], potential 
mechanisms behind the beneficial effects of the Mediterra-
nean and Palaeolithic diets could be attributed to their anti-
oxidative and anti-inflammatory capacity [41, 46]. Thus, 
both the Mediterranean diet and the Palaeolithic diet share 
common features that render them as healthy options in 
patients with type 2 diabetes, and represent a step forward 
for an optimal human diet.
Vegetarian diets are regarded as a healthy option for 
western diseases as well. A recent systematic review and 
meta-analysis investigated the effects of a vegetarian diet 
on glycemic control in type 2 diabetes [47], resulting in 
better HbA1c, but not fasting glucose, than control diets. 
None of the the included trials tested a vegetarian diet 
against a Palaeolithic or Mediterranean diet.
Importantly, a systematic review and meta-analysis 
assessed the effect of various diets on glycemic control in 
type 2 diabetes [48]. The results indicate that all the diets, 
namely low-carbohydrate, low-glycaemic index, Mediter-
ranean and high-protein diets, improved HbA1c com-
pared with their respective control diets. Consequently, 
the best dietary approach for the management of type 2 
diabetes continues to be a matter of debate.
Limitations of the present study
A limitation of this study, as with most other dietary tri-
als, is the lack of blinding after randomisation. To mini-
mise this problem, all study participants were informed 
of the intention to compare the effect of two healthy diets 
for the treatment of type 2 diabetes and that it was not 
known which one would be superior. Also, written infor-
mation with dietary advice, food recipes and behavioural 
support were similarly formulated for both diets. The 
difference in weight loss, macronutrient composition 
and glycaemic load between the diets precludes a defi-
nite conclusion about the specific role of different food 
choices on the endocrine system.
The results of this study should be interpreted with 
caution for other reasons as well. First, we have the limi-
tation of multiple outcome measures problem and the 
probability of type I error for leptin in our study is 20.8 %. 
Secondly, the outcomes generated from this post hoc 
analysis represent exploratory investigations; the primary 
outcomes have been previously published. Lastly, this 
study has a small sample size which precludes us from 
performing adjusted multivariate analysis. This is spe-
cially relevant for weight loss because it decreased only 
during the diabetes diet and the difference after the diets 
was 3.3 kg (p = 0.008). As a result, since weight loss is a 
principal driver of improved leptin sensitivity we are not 
certain about the independent effect of the diets on the 
results.
Conclusion
We show that a Palaeolithic diet results in significantly 
lower fasting plasma leptin, non-significantly lower fast-
ing plasma glucagon concentrations as well as weight 
loss, compared to a standard diabetes diet. Human 
beings are well adapted to food groups similar to those 
found in the Palaeolithic era during our evolution, and, 
hypothetically, the lower leptin and glucagon levels could 
indicate that deviations from this template is not optimal 
and could explain our previously reported findings on 
glucose control, blood lipids, blood pressure and satiety. 
But the small sample size of the present study makes it 
impossible to perform adjusted multivariate analysis and 
the observed weight loss after the Palaeolithic diet may 
also contribute to explain our results. Long-term and 
adequately powered trials investigating the effects of Pal-
aeolithic diet are warranted.
Additional file
Additional file 1. Supporting data set. Data set supporting our results on 
hormones (adipokines, glucagon and incretins), post hoc analysis and pre‑
viously published outcomes (worksheet ‘Data set’). Each row numbered 
1‑13 in first column ‘Person‑ID’ corresponds to data from one participant. 
Each column heading contains a variable name stating what individual 
mean has been measured, in what unit and whether on the Paleolithic 
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able names and their description are listed below.
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